Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2004

View Archived Issues

Amino acid conjugated small molecule lowers blood glucose in insulin-resistant mice

Curis' first quarter highlighted by two key events

Abgenix reports recent company highlights

High-dose capsaicin is a useful adjunct in painful diabetic neuropathy and postherpetic neuralgia

Intramuscular tetrodotoxin may be useful in the treatment of severe cancer pain

DeveloGen and Peptor finalize merger

Lipoxen and Adjuvantix to develop new conjugate vaccines

ICS-205930 enhances naltrexone-induced suppression of ethanol consumption

Atugen and Sankyo establish research agreement

Celltech and UCB establish development and marketing agreement for CDP-870

GSK commences phase III trial of new cervical cancer vaccine

Sanochemia reports positive results of phase III trial of galantamine in postoperative delirium

JYL-1421 and acid stimulation of esophageal afferent neurons in rats

FDA approves Vidaza for treatment of MDS

SciClone meets enrollment objective in phase III hepatitis C trial

Biosyn begins phase III pivotal trial of lead product for prevention of HIV transmission

Peninsula initiates phase I trial of PPI-0903

CyrRx in-licenses intellectual property covering drug screening method using Rip140

Innovative Companies changes name to GeoPharma

Potential benefits of SLV-317 in irritable bowel syndrome

Therapeutic benefits of adalimumab in Crohn's disease

Statin therapy examined in nonischemic dilated cardiomyopathy

Argatroban pharmacokinetics studied in hemodialysis patients

Small molecule Lck inhibitors promote long-term allograft survival

Novel selective S1P receptor agonist shows prolonged effect in animal transplant models

Secretin shows promise in refractory schizophrenia

New cathepsin G, chymase and elatase inhibitors isolated from fungal cultures

New antibacterial DNA gyrase inhibitors identified at Pfizer

Banyu researchers design novel NPY antagonists

Novel gamma-secretase inhibitors and their use claimed by AstraZeneca

New CDK inhibitors for cancer and other disorders under study at Sanofi-Synthelabo

Non-estrogenic ER ligands with potential utility as antiinflammatory agents

JNK3/PP1 inhibitors of fungal origin and their use in neurological disorders

Safinamide treatment benefits epilepsy, Parkinson's disease patients

Two series of tyrosine kinase inhibitors described by BMS researchers